Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS

   Terminated · Phase 2, Phase 3 · Nakajo-Nishimura Syndrome

   NCT04517253 · Eli Lilly and Company · 0 U.S. investigators

   $8,100research payments

2. A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin

   Completed · Phase 1 · Healthy Volunteers

   NCT07118215 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

   $8,090research payments

3. A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

   Active, not recruiting · Phase 1 · Advanced Solid Tumors

   NCT06544655 · E.r. Squibb & Sons, L.l.c. · 3 U.S. investigators

   $8,016research payments

4. Eptinezumab in Participants With Episodic Cluster Headache

   Completed · Phase 3 · Cluster Headache, Episodic

   NCT04688775 · H. Lundbeck A S · 3 U.S. investigators

   $7,968research payments

5. G7 Acetabular System With Vivacit-E or Longevity Liner PMCF Study

   Active, not recruiting · Not applicable · Total Hip Arthroplasty

   NCT04754087 · Zimmer Biomet Holdings, Inc. · 1 U.S. investigator

   $7,954research payments

6. Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)

   Completed · Phase 2 · Cocaine Use Disorder

   NCT05262270 · Indivior Inc. · 1 U.S. investigator

   $7,922research payments

7. A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants

   Completed · Phase 1 · Healthy Study Participants

   NCT06970301 · UCB SA · 1 U.S. investigator

   $7,921research payments

8. A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

   Terminated · Phase 1, Phase 2 · Renal Cell Carcinoma (RCC)

   NCT03311334 · Sumitomo Pharma America, Inc. · 1 U.S. investigator

   $7,913research payments

9. A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

   Completed · Phase 3 · Renal Cell Carcinoma

   NCT03141177 · E.r. Squibb & Sons, L.l.c. · 3 U.S. investigators

   $7,820research payments

10. A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder

    Recruiting · Phase 4 · Opioid Use Disorder

    NCT04375033 · Indivior Inc. · 6 U.S. investigators

    $7,784research payments

11. Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)

    Terminated · Phase 2 · Non-small Cell Lung Cancer Metastatic

    NCT04394624 · Sanofi US Services Inc. · 1 U.S. investigator

    $7,643research payments

12. [Trial of device that is not approved or cleared by the U.S. FDA]

    Withheld

    NCT05982782 · Neurent Medical Limited · 0 U.S. investigators

    $7,595research payments

13. Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

    Terminated · Phase 3 · Giant Cell Arteritis

    NCT03600805 · Sanofi US Services Inc. · 1 U.S. investigator

    $7,455research payments

14. A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

    Completed · Phase 3 · Non Small Cell Lung Cancer

    NCT02998528 · E.r. Squibb & Sons, L.l.c. · 3 U.S. investigators

    $7,342research payments

15. A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)

    Terminated · Phase 2 · Squamous Cell Carcinoma of Head and Neck

    NCT05061420 · Sanofi US Services Inc. · 1 U.S. investigator

    $7,228research payments

16. A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

    Terminated · Phase 2 · Prostatic Neoplasms, Castration-Resistant

    NCT05169684 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

    $7,165research payments

17. Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

    Completed · Moderate-to-severe Atopic Dermatitis

    NCT05203380 · Regeneron Pharmaceuticals, Inc. · 0 U.S. investigators

    $7,141research payments

18. A Study of Sepiapterin in Participants With Phenylketonuria (PKU)

    Recruiting · Phase 3 · Phenylketonuria

    NCT06302348 · Ptc Therapeutics, Inc. · 1 U.S. investigator

    $7,116research payments

19. A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

    Recruiting · Phase 1 · Hepatocellular Cancer

    NCT06858813 · AbbVie Inc. · 10 U.S. investigators

    $7,096research payments

20. S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

    Completed · Phase 3 · Prostate Cancer

    NCT01809691 · Menarini Silicon Biosystems, Inc. · 1 U.S. investigator

    $7,085research payments

21. Angiotensin II in Liver Transplantation

    Active, not recruiting · Phase 2, Phase 3 · Liver Transplant

    NCT04901169 · La Jolla Pharmaceutical Company · 1 U.S. investigator

    $7,060research payments

22. A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

    Active, not recruiting · Phase 3 · Metastatic Non-Small Cell Lung Cancer

    NCT02411448 · Eli Lilly and Company · 1 U.S. investigator

    $7,025research payments

23. Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer

    Completed · Phase 1 · Non-small Cell Lung Cancer

    NCT06091943 · Beigene USA, Inc. · 1 U.S. investigator

    $6,988research payments

24. Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement

    Active, not recruiting · Phase 2 · Cirrhosis

    NCT06052176 · Grifols Shared Services North America, Inc. · 1 U.S. investigator

    $6,962research payments

25. A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder

    Completed · Phase 2 · Alcohol Use Disorder

    NCT06817356 · Eli Lilly and Company · 18 U.S. investigators

    $6,907research payments

26. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

    Completed · Phase 3 · Healthy Volunteers (Meningococcal Infection)

    NCT03537508 · Sanofi Pasteur Inc. · 3 U.S. investigators

    $6,878research payments

27. A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

    Recruiting · Phase 3 · Carcinoma, Non-Small-Cell Lung

    NCT06875310 · E.r. Squibb & Sons, L.l.c. · 2 U.S. investigators

    $6,775research payments

28. Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients

    Completed · Phase 3 · Plasma Cell Myeloma

    NCT03275285 · Sanofi US Services Inc. · 0 U.S. investigators

    $6,768research payments

29. An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

    Terminated · Phase 1 · Cancer

    NCT04189614 · AbbVie Inc. · 2 U.S. investigators

    $6,742research payments

30. Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)

    Completed · Phase 3 · Dermatitis, Atopic

    NCT03345914 · Regeneron Pharmaceuticals, Inc. · 0 U.S. investigators

    $6,712research payments

31. A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

    Completed · Phase 2 · Lipoprotein Disorder

    NCT05563246 · Eli Lilly and Company · 1 U.S. investigator

    $6,630research payments

32. A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants

    Completed · Phase 1 · Healthy Volunteer

    NCT06849791 · AbbVie Inc. · 0 U.S. investigators

    $6,507research payments

33. To Study the Effect of Early Cooling in Acute Subdural Hematoma Patients

    Terminated · Not applicable · Subdural Hematoma, Traumatic

    NCT02064959 · Zoll Circulation Inc · 4 U.S. investigators

    $6,500research payments

34. A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

    Recruiting · Phase 4 · Psoriasis

    NCT06857942 · Eli Lilly and Company · 1 U.S. investigator

    $6,500research payments

35. A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants

    Completed · Phase 2 · Gram-negative Bacterial Infections

    NCT04215991 · Shionogi Inc · 1 U.S. investigator

    $6,315research payments

36. Restoration® Anatomic Dual Mobility (ADM) X3® Acetabular System Study

    Terminated · Not applicable · Arthroplasty, Replacement, Hip

    NCT01420237 · Stryker Corporation · 4 U.S. investigators

    $6,301research payments

37. LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

    Recruiting · Phase 2 · Ulcerative Colitis

    NCT07186101 · Eli Lilly and Company · 12 U.S. investigators

    $6,299research payments

38. Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)

    Completed · Phase 2 · Coronavirus Disease 2019 (COVID-19)

    NCT04409509 · Csl Behring · 2 U.S. investigators

    $6,281research payments

39. A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B

    Active, not recruiting · Phase 2 · Usher's Syndrome

    NCT02065011 · Genzyme Corporation · 1 U.S. investigator

    $6,274research payments

40. A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants

    Completed · Phase 3 · Cytomegalovirus (CMV)

    NCT02927067 · Takeda Pharmaceuticals U.S.A., Inc. · 1 U.S. investigator

    $6,269research payments

41. Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study

    Completed · Phase 2 · Eczema

    NCT05131477 · Genzyme Corporation · 0 U.S. investigators

    $6,250research payments

42. Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants

    Terminated · Phase 1 · Meningococcal Immunisation

    NCT04825223 · Sanofi Pasteur Inc. · 3 U.S. investigators

    $6,204research payments

43. A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

    Active, not recruiting · Phase 3 · Acute Myeloid Leukemia (AML)

    NCT02993523 · AbbVie Inc. · 1 U.S. investigator

    $6,203research payments

44. Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP

    Completed · Not applicable · Sudden Cardiac Death

    NCT02923726 · Boston Scientific Corporation · 2 U.S. investigators

    $6,196research payments

45. A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

    Active, not recruiting · Phase 1, Phase 2 · Hodgkin Disease

    NCT02979522 · Takeda Pharmaceuticals U.S.A., Inc. · 2 U.S. investigators

    $6,189research payments

46. A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

    Completed · Phase 2 · Oesophageal Squamous Cell Carcinoma

    NCT05104567 · Sanofi US Services Inc. · 1 U.S. investigator

    $6,150research payments

47. Deep Brain Stimulation (DBS) Retrospective Outcomes Study

    Recruiting · Parkinson Disease

    NCT03664609 · Boston Scientific Corporation · 4 U.S. investigators

    $6,105research payments

48. Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis

    Completed · Phase 3 · Ulcerative Colitis

    NCT02632175 · AbbVie Inc. · 1 U.S. investigator

    $6,100research payments

49. Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy

    Recruiting · Phase 4 · Factor VIII Deficiency

    NCT06941870 · Sanofi US Services Inc. · 1 U.S. investigator

    $6,038research payments

50. A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

    Active, not recruiting · Phase 2 · Lymphoma, Follicular

    NCT06425302 · E.r. Squibb & Sons, L.l.c. · 10 U.S. investigators

    $6,001research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.